Back to Search

GITASREE BORTHAKUR, M.D.

M.D.

Diagnostic Radiology Physician

NPI: 1891054656IndividualAccepts Medicare

Specialties, Licenses & Credentials

Diagnostic Radiology PhysicianPrimary

Radiology — Diagnostic Radiology

Code: 2085R0202X

A148478(CA)

CMS Specialties

PrimaryDIAGNOSTIC RADIOLOGY

Education

NORTHEASTERN OHIO UNIVERSITY COLLEGE OF MEDICINE

Class of 2012

Research & Publications (20)

Exfoliated buccal mucosa cells as a source of DNA to study oxidative stress.
PMID 18199726·Cancer Epidemiol Biomarkers Prev·2008
2-rct
Sulfatides inhibit platelet adhesion to von Willebrand factor in flowing blood.
PMID 12871332·J Thromb Haemost·2003
8-other
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
PMID 19517462·Cancer·2009
8-other
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
PMID 19441109·Cancer·2009
8-other
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
PMID 19517473·Cancer·2009
3-trial
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
PMID 19652057·J Clin Oncol·2009
3-trial
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
PMID 19369233·Blood·2009
8-other
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
PMID 19567878·Blood·2009
8-other
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
PMID 19531657·Blood·2009
8-other
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
PMID 19282457·Blood·2009
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Address
9998 CROSSPOINT BLVD, STE 200
INDIANAPOLIS, IN 46256

Quick Facts

NPI
1891054656
Entity Type
Individual
Gender
Female
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
14
Publications
20

Are you this provider?

Claim Your Profile